<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995838</url>
  </required_header>
  <id_info>
    <org_study_id>E2006-G000-201</org_study_id>
    <nct_id>NCT01995838</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled,
      parallel-group, Bayesian adaptive, dose response study in subjects with chronic insomnia.
      Subjects will be randomized to 1 of 6 doses of E2006 (1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25
      mg) or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have 2 phases, Prerandomization and Randomization. The Prerandomization Phase
      will last up to 21 days and will consist of a Screening Period (Days -21 to -2) and a
      Baseline Period (Day -1). Following the Baseline Period, all eligible subjects will be
      randomized, in a double-blind manner, to receive E2006 or placebo for 15 nights during the
      Treatment Period (Days 1 to 15), then all subjects will receive placebo, in a single-blind
      manner, for 2 nights (Days 16 to 17) during the Rebound Insomnia Assessment Period (Days 16
      to 18). Subjects will not receive any treatment during the Follow-up Period (Days 19 to 29).
      All subjects will come to the clinic for screening procedures. During the Screening Period,
      subjects will complete the Sleep Diary each day. Polysomnographic sleep will be measured
      during the Screening Period on 2 consecutive nights between Day -9 and Day -3. These 8-hour
      polysomnograms (PSGs) will start at the median habitual bedtime calculated from responses on
      the Sleep Diary completed 7 days immediately prior to the first PSG night. Subjects may leave
      the clinic between the screening/baseline PSG nights.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2013</start_date>
  <completion_date type="Actual">April 29, 2014</completion_date>
  <primary_completion_date type="Actual">April 29, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of Having Utility Function Greater Than (&gt;) 1 Based on Bayesian Analysis</measure>
    <time_frame>Baseline up to Day 3</time_frame>
    <description>The utility of a dose was a function of both Sleep Efficiency (SE) and Karolinska Sleepiness Scale (KSS), constructed by specifying the 1-dimensional component for each outcome measure and then combining them multiplicatively. Sufficient utility was defined as a probability of having utility function &gt;1. Probability of having utility function &gt;1 at the end of study visit (full analysis) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Karolinska Sleepiness Scale (KSS) Score at End of Treatment</measure>
    <time_frame>1 hour after morning wake time at Baseline and Days 15-16</time_frame>
    <description>The KSS was used to measure next-day residual effects at prespecified time points. The KSS was a 9-point scale on which the participant rated their sleepiness from 1 (extremely alert) to 9 (extremely sleepy/fighting sleep), where higher scores indicated an increase in sleepiness. The end of treatment score was calculated by the mean scores at the timepoint at 1 hour after morning wake time of Day 15 and 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 1-2 and Days 14-15</measure>
    <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
    <description>Sleep efficiency was calculated as total sleep time divided by time spent in bed multiplied by 100. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Latency to Persistent Sleep (LPS) After Dosing on Days 1-2 and Days 14-15</measure>
    <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
    <description>LPS was calculated as minutes from lights off to the first 30-second epoch of 20 consecutive epochs of non-wakefulness. A decrease in LPS indicated improvement in time needed to fall asleep. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) After Dosing on Days 1-2 and Days 14-15</measure>
    <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
    <description>WASO was calculated as minutes of wakefulness from the onset of persistent sleep until lights on. A decrease in WASO indicated improvement in sleep maintenance. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential Habituation Effect: Comparison Between Mean Change From Baseline in SE on Days 1-2 and Mean Change From Baseline in SE on Days 14-15</measure>
    <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
    <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean SE of Days 14-15 minus change from baseline of mean SE of Days 1-2. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential Habituation Effect: Comparison Between Mean Change From Baseline in Latency to Persistent Sleep (LPS) on Days 1-2 and Mean Change From Baseline in LPS on Days 14-15</measure>
    <time_frame>Baseline and Days 1-2, and Days 14-15</time_frame>
    <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean LPS of Days 14-15 minus change from baseline of mean LPS of Days 1-2. LPS was calculated as minutes from lights off to the first 30-second epoch of 20 consecutive epochs of non-wakefulness. A decrease in LPS indicated improvement in time needed to fall asleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential Habituation Effect: Comparison Between Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) on Days 1-2 and Mean Change From Baseline in WASO on Days 14-15</measure>
    <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
    <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean WASO of Days 14-15 minus change from baseline of mean WASO of Days 1-2. WASO was calculated as minutes of wakefulness from the onset of persistent sleep until lights on. A decrease in WASO indicated improvement in sleep maintenance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebound Insomnia: Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 16-17</measure>
    <time_frame>Baseline and Days 16-17</time_frame>
    <description>Rebound insomnia was assessed by comparing the change from baseline of the mean SE on Days 16-17. Sleep efficiency was calculated as total sleep time divided by time spent in bed multiplied by 100. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep. A negative change from baseline in SE indicated that SE was worse on Days 16 and 17 than at Baseline, which was considered as evidence for rebound insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)</measure>
    <time_frame>TEAEs: Baseline up to Day 30, SAEs: Baseline up to 30 days after last dose of study drug (up to 47 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Parameters</measure>
    <time_frame>Baseline up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Baseline up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECGs)</measure>
    <time_frame>Baseline up to Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Chronic Insomnia</condition>
  <condition>Adults</condition>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>E2006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2006</intervention_name>
    <description>E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights</description>
    <arm_group_label>E2006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects must meet all of the following criteria to be included in this study:

          1. Male or female subjects age 18 to 80 years at the time of informed consent

          2. Meets the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders
             (DSM-5) criteria for Insomnia Disorder

          3. Subjective Sleep Onset Latency (sSOL) typically greater than or equal to 30 minutes in
             the last 4 weeks and/or subjective WASO (sWASO) typically greater than or equal to 60
             minutes in the last 4 weeks

          4. Regular time in bed between 6.5 and 9.0 hours

          5. Regular bedtime between 21:00 and 24:00 and regular waketime between 05:00 and 09:00

          6. Insomnia Severity Index (ISI) score greater than or equal to 15 at Screening

          7. Confirmation of current insomnia symptoms as determined from responses on the Sleep
             Diary completed for 7 nights prior to the first screening/baseline PSG

          8. Objective (PSG) evidence of insomnia at the screening/baseline PSGs as follows:

               1. LPS average greater than or equal to 30 minutes on the 2 consecutive
                  screening/baseline PSGs, with neither night lesser than 15 minutes and/or

               2. WASO average greater than or equal to 30 minutes on the 2 consecutive
                  screening/baseline PSGs, with neither night lesser than 20 minutes

               3. SE average lesser than or equal to 85% on the 2 consecutive screening/baseline
                  PSGs, with neither night greater than 87.5%

          9. Females of childbearing potential must not have had unprotected sexual intercourse
             within 30 days before study entry and must agree to use two highly effective method of
             contraception

         10. Male subjects must have had a successful vasectomy (confirmed azoospermia) or they and
             their female partners must meet the criteria above (i.e., not of childbearing
             potential or practicing highly effective contraception throughout the study period and
             for 30 days after study drug discontinuation). No sperm donation is allowed during the
             study period and for 30 days after study drug discontinuation.

         11. Provide written informed consent

         12. Willing to stay in bed for at least 8 hours each night spent in the clinic

         13. Willing and able to comply with all aspects of the protocol

        Exclusion Criteria

        Subjects who meet any of the following criteria will be excluded from this study:

          1. Females who are pregnant (positive beta-human chorionic gonadotropin [B-hCG] test) or
             breastfeeding

          2. Any lifetime diagnosis of sleep-related breathing disorder, periodic limb movement
             disorder, restless legs syndrome, nightmare disorder, sleep terror disorder,
             sleepwalking disorder, rapid eye movement (REM) behavior disorder, or narcolepsy

          3. Aged 18 to 64 years: Apnea-Hypopnea Index greater than or equal to 10, or Periodic
             Limb Movements with Arousal Index greater than or equal to 10 on first (diagnostic)
             PSG night at Screening. Aged 65 to 80 years: Apnea-Hypopnea Index greater than 15, or
             Periodic Limb Movements with Arousal Index greater than 15 on first (diagnostic) PSG
             night at Screening

          4. Beck Depression Inventory (BDI) - II score greater than 19 at Screening

          5. Beck Anxiety Inventory (BAI) score greater than 15 at Screening

          6. Used a prescription for any modality of treatment for insomnia, including cognitive
             behavioral therapy, within 2 weeks prior to screening/baseline PSG, or between
             Screening and Baseline

          7. Used any medication or sleep aid with known effects on sleep, within 2 weeks prior to
             screening/baseline PSG, or between Screening and Baseline

          8. Used any prohibited prescription or over-the-counter concomitant medications within
             the week prior to the first screening/baseline PSG.

          9. Transmeridian travel across 3 or more time zones in the 2 weeks prior to Screening, or
             plans to travel across 3 or more time zones during study

         10. Unwilling to limit caffeine consumption to lesser than or equal to 600 mg caffeine
             (approximately four 6-oz cups of caffeinated coffee, or three 12-oz caffeinated sodas,
             or three 8-oz caffeinated tea beverages), avoid caffeine after 18:00 throughout the
             study, and avoid caffeine after 13:00 on PSG visits

         11. Unwilling to limit alcohol intake to two or fewer drinks per day throughout the study,
             or to refrain from any alcohol for 3 hours prior to bedtime while at home throughout
             the study, or any alcohol on days and nights spent in the clinic. A drink is defined
             as approximately 12 oz (360 mL) of beer, 4 oz (120 mL) of wine, or 1 oz (30 mL) of
             liquor.

         12. Any subject that has a known history of malaria or has traveled to a country with
             known malarial risk (i.e., are designated as 'high' or 'moderate' risk country
             according to the list available at http://www.cdc.gov/malaria) within the last year.

         13. A prolonged QT/QT interval corrected for heart rate (QTc) interval (QTc greater than
             450 ms) as demonstrated by a repeated electrocardiogram (ECG) at Screening (repeated
             only if initial ECG indicates a QTc interval greater than 450 ms). A history of risk
             factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of
             long QT Syndrome) or the use of concomitant medications that prolong the QT/QTc
             interval.

         14. Any suicidal ideation with intent with or without a plan at Screening, Baseline, or
             within 6 months before Screening (i.e., answering &quot;Yes&quot; to questions 4 or 5 on the
             Suicidal Ideation section of the Columbia-Suicide Severity Rating Scale [C-SSRS])

         15. Any lifetime suicidal behavior (per the Suicidal Behavior Section of the C-SSRS)

         16. Evidence of clinically significant disease (e.g., cardiac, respiratory,
             gastrointestinal, renal disease) that in the opinion of the investigator(s) could
             affect the subject's safety or interfere with the study assessments

         17. Hypersensitivity to the study drug or any of the excipients

         18. Any history of a medical condition or a concomitant medical condition that in the
             opinion of the investigator(s) would compromise the subject's ability to safely
             complete the study

         19. Scheduled for surgery during the study

         20. Known to be human immunodeficiency virus (HIV) positive

         21. Active viral hepatitis (B or C) as demonstrated by positive serology

         22. Psychotic disorder(s) or unstable recurrent affective disorder(s) evident by use of
             antipsychotics or prior suicide attempt(s) within approximately the last 2 years

         23. History of drug or alcohol dependency or abuse within approximately the last 2 years

         24. Unwilling to refrain from use of illegal (or legalized) recreational drugs during the
             study or test positive for illegal (or legalized) drugs at Screening, Baseline, or Day
             14

         25. Currently enrolled in another clinical trial or used any investigational drug or
             device within 30 days or 5x the half-life, whichever is longer preceding informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201-2953</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <results_first_submitted>September 5, 2018</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2020</results_first_posted>
  <disposition_first_submitted>June 25, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 25, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 20, 2015</disposition_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Insomnia</keyword>
  <keyword>Adults</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 23 investigative sites in the United States from 13 Nov 2013 to 29 Apr 2014.</recruitment_details>
      <pre_assignment_details>A total of 616 participants were screened, of which 325 were screen failures and 291 were randomized to receive study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="P2">
          <title>Lemborexant 1 Milligram (mg)</title>
          <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="P3">
          <title>Lemborexant 2.5 mg</title>
          <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="P4">
          <title>Lemborexant 5 mg</title>
          <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="P5">
          <title>Lemborexant 10 mg</title>
          <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="P6">
          <title>Lemborexant 15 mg</title>
          <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="P7">
          <title>Lemborexant 25 mg</title>
          <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="56"/>
                <participants group_id="P7" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant choice</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Lemborexant 1 mg</title>
          <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="B2">
          <title>Lemborexant 2.5 mg</title>
          <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="B3">
          <title>Lemborexant 5 mg</title>
          <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="B4">
          <title>Lemborexant 10 mg</title>
          <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="B5">
          <title>Lemborexant 15 mg</title>
          <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="B6">
          <title>Lemborexant 25 mg</title>
          <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="B7">
          <title>Placebo</title>
          <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="56"/>
            <count group_id="B6" value="50"/>
            <count group_id="B7" value="56"/>
            <count group_id="B8" value="291"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.3" spread="13.0"/>
                    <measurement group_id="B2" value="49.7" spread="14.3"/>
                    <measurement group_id="B3" value="51.1" spread="14.3"/>
                    <measurement group_id="B4" value="47.1" spread="13.7"/>
                    <measurement group_id="B5" value="44.0" spread="14.6"/>
                    <measurement group_id="B6" value="48.9" spread="13.4"/>
                    <measurement group_id="B7" value="47.1" spread="15.6"/>
                    <measurement group_id="B8" value="48.3" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="36"/>
                    <measurement group_id="B8" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Probability of Having Utility Function Greater Than (&gt;) 1 Based on Bayesian Analysis</title>
        <description>The utility of a dose was a function of both Sleep Efficiency (SE) and Karolinska Sleepiness Scale (KSS), constructed by specifying the 1-dimensional component for each outcome measure and then combining them multiplicatively. Sufficient utility was defined as a probability of having utility function &gt;1. Probability of having utility function &gt;1 at the end of study visit (full analysis) was reported.</description>
        <time_frame>Baseline up to Day 3</time_frame>
        <population>The full analysis set (FAS) included all participants who were randomized, received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Probability of Having Utility Function Greater Than (&gt;) 1 Based on Bayesian Analysis</title>
          <description>The utility of a dose was a function of both Sleep Efficiency (SE) and Karolinska Sleepiness Scale (KSS), constructed by specifying the 1-dimensional component for each outcome measure and then combining them multiplicatively. Sufficient utility was defined as a probability of having utility function &gt;1. Probability of having utility function &gt;1 at the end of study visit (full analysis) was reported.</description>
          <population>The full analysis set (FAS) included all participants who were randomized, received at least 1 dose of study drug and had at least 1 postdose primary efficacy measurement.</population>
          <units>probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8789"/>
                    <measurement group_id="O2" value="0.8920"/>
                    <measurement group_id="O3" value="0.9032"/>
                    <measurement group_id="O4" value="0.9406"/>
                    <measurement group_id="O5" value="0.9866"/>
                    <measurement group_id="O6" value="0.9675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Karolinska Sleepiness Scale (KSS) Score at End of Treatment</title>
        <description>The KSS was used to measure next-day residual effects at prespecified time points. The KSS was a 9-point scale on which the participant rated their sleepiness from 1 (extremely alert) to 9 (extremely sleepy/fighting sleep), where higher scores indicated an increase in sleepiness. The end of treatment score was calculated by the mean scores at the timepoint at 1 hour after morning wake time of Day 15 and 16.</description>
        <time_frame>1 hour after morning wake time at Baseline and Days 15-16</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, number of participants analyzed (N) represents participants who were available for analysis at the specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Karolinska Sleepiness Scale (KSS) Score at End of Treatment</title>
          <description>The KSS was used to measure next-day residual effects at prespecified time points. The KSS was a 9-point scale on which the participant rated their sleepiness from 1 (extremely alert) to 9 (extremely sleepy/fighting sleep), where higher scores indicated an increase in sleepiness. The end of treatment score was calculated by the mean scores at the timepoint at 1 hour after morning wake time of Day 15 and 16.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, number of participants analyzed (N) represents participants who were available for analysis at the specified timepoints.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.219"/>
                    <measurement group_id="O2" value="-0.10" spread="0.234"/>
                    <measurement group_id="O3" value="0.20" spread="0.200"/>
                    <measurement group_id="O4" value="-0.22" spread="0.219"/>
                    <measurement group_id="O5" value="0.16" spread="0.166"/>
                    <measurement group_id="O6" value="0.45" spread="0.180"/>
                    <measurement group_id="O7" value="-0.23" spread="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0651</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6490</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1059</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0. 9818</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0. 54</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0. 1071</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0063</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 1-2 and Days 14-15</title>
        <description>Sleep efficiency was calculated as total sleep time divided by time spent in bed multiplied by 100. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
        <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug, had at least 1 post-dose primary efficacy measurement with both baseline and post baseline data available for analysis at each timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 1-2 and Days 14-15</title>
          <description>Sleep efficiency was calculated as total sleep time divided by time spent in bed multiplied by 100. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug, had at least 1 post-dose primary efficacy measurement with both baseline and post baseline data available for analysis at each timepoints.</population>
          <units>percentage of sleep time</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.72" spread="1.366"/>
                    <measurement group_id="O2" value="18.59" spread="1.487"/>
                    <measurement group_id="O3" value="19.89" spread="1.250"/>
                    <measurement group_id="O4" value="22.25" spread="1.361"/>
                    <measurement group_id="O5" value="24.22" spread="1.029"/>
                    <measurement group_id="O6" value="24.28" spread="1.091"/>
                    <measurement group_id="O7" value="14.16" spread="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 14-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.43" spread="1.428"/>
                    <measurement group_id="O2" value="18.02" spread="1.528"/>
                    <measurement group_id="O3" value="19.85" spread="1.302"/>
                    <measurement group_id="O4" value="21.87" spread="1.421"/>
                    <measurement group_id="O5" value="21.97" spread="1.077"/>
                    <measurement group_id="O6" value="22.96" spread="1.169"/>
                    <measurement group_id="O7" value="14.08" spread="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0083</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>7.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0151</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>8.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.54</ci_lower_limit>
            <ci_upper_limit>8.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.73</ci_lower_limit>
            <ci_upper_limit>11.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>10.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.20</ci_lower_limit>
            <ci_upper_limit>12.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>10.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.18</ci_lower_limit>
            <ci_upper_limit>13.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8505</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.22</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0380</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>7.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.40</ci_lower_limit>
            <ci_upper_limit>9.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.24</ci_lower_limit>
            <ci_upper_limit>11.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.86</ci_lower_limit>
            <ci_upper_limit>10.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.72</ci_lower_limit>
            <ci_upper_limit>12.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Latency to Persistent Sleep (LPS) After Dosing on Days 1-2 and Days 14-15</title>
        <description>LPS was calculated as minutes from lights off to the first 30-second epoch of 20 consecutive epochs of non-wakefulness. A decrease in LPS indicated improvement in time needed to fall asleep. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
        <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug, had at least 1 post-dose primary efficacy measurement with both baseline and post baseline data available for analysis at each timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Latency to Persistent Sleep (LPS) After Dosing on Days 1-2 and Days 14-15</title>
          <description>LPS was calculated as minutes from lights off to the first 30-second epoch of 20 consecutive epochs of non-wakefulness. A decrease in LPS indicated improvement in time needed to fall asleep. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug, had at least 1 post-dose primary efficacy measurement with both baseline and post baseline data available for analysis at each timepoints.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.92" spread="41.855"/>
                    <measurement group_id="O2" value="-52.74" spread="50.149"/>
                    <measurement group_id="O3" value="-47.72" spread="39.389"/>
                    <measurement group_id="O4" value="-46.80" spread="46.106"/>
                    <measurement group_id="O5" value="-51.59" spread="36.728"/>
                    <measurement group_id="O6" value="-50.16" spread="43.140"/>
                    <measurement group_id="O7" value="-22.90" spread="44.457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 14-15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.23" spread="34.618"/>
                    <measurement group_id="O2" value="-54.24" spread="44.918"/>
                    <measurement group_id="O3" value="-51.86" spread="41.994"/>
                    <measurement group_id="O4" value="-56.14" spread="45.553"/>
                    <measurement group_id="O5" value="-51.95" spread="41.926"/>
                    <measurement group_id="O6" value="-50.79" spread="40.160"/>
                    <measurement group_id="O7" value="-22.43" spread="29.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1407</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Days 1-2</non_inferiority_desc>
            <p_value>0.0018</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2:</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1158</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) After Dosing on Days 1-2 and Days 14-15</title>
        <description>WASO was calculated as minutes of wakefulness from the onset of persistent sleep until lights on. A decrease in WASO indicated improvement in sleep maintenance. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
        <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, number of participants analyzed (N) represents participants who were available for analysis at the specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) After Dosing on Days 1-2 and Days 14-15</title>
          <description>WASO was calculated as minutes of wakefulness from the onset of persistent sleep until lights on. A decrease in WASO indicated improvement in sleep maintenance. Mean scores of Days 1-2 and Days 14-15 were used to evaluate change from baseline.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, number of participants analyzed (N) represents participants who were available for analysis at the specified timepoints.</population>
          <units>minutes</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1-2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="56"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.11" spread="5.441"/>
                    <measurement group_id="O2" value="-43.33" spread="5.915"/>
                    <measurement group_id="O3" value="-52.29" spread="5.423"/>
                    <measurement group_id="O4" value="-60.84" spread="1.302"/>
                    <measurement group_id="O5" value="-70.38" spread="4.103"/>
                    <measurement group_id="O6" value="-66.87" spread="4.342"/>
                    <measurement group_id="O7" value="-41.03" spread="4.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 14-15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="46"/>
                    <count group_id="O7" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.46" spread="6.159"/>
                    <measurement group_id="O2" value="-40.47" spread="6.581"/>
                    <measurement group_id="O3" value="-48.84" spread="5.609"/>
                    <measurement group_id="O4" value="-52.88" spread="6.129"/>
                    <measurement group_id="O5" value="-58.95" spread="4.651"/>
                    <measurement group_id="O6" value="-59.67" spread="5.039"/>
                    <measurement group_id="O7" value="-38.15" spread="4.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1050</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.48</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7501</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.46</ci_lower_limit>
            <ci_upper_limit>11.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0818</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.94</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0038</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-19.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.18</ci_lower_limit>
            <ci_upper_limit>-6.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-29.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.75</ci_lower_limit>
            <ci_upper_limit>17.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 1-2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-25.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.59</ci_lower_limit>
            <ci_upper_limit>-14.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4642</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.4642</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.60</ci_lower_limit>
            <ci_upper_limit>20.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Baseline value and treatment as covariates.</non_inferiority_desc>
            <p_value>0.7754</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.27</ci_lower_limit>
            <ci_upper_limit>13.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1461</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.14</ci_lower_limit>
            <ci_upper_limit>3.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0581</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-14.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.97</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-20.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.86</ci_lower_limit>
            <ci_upper_limit>-7.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 14-15</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-21.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.12</ci_lower_limit>
            <ci_upper_limit>-7.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potential Habituation Effect: Comparison Between Mean Change From Baseline in SE on Days 1-2 and Mean Change From Baseline in SE on Days 14-15</title>
        <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean SE of Days 14-15 minus change from baseline of mean SE of Days 1-2. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep.</description>
        <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Potential Habituation Effect: Comparison Between Mean Change From Baseline in SE on Days 1-2 and Mean Change From Baseline in SE on Days 14-15</title>
          <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean SE of Days 14-15 minus change from baseline of mean SE of Days 1-2. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percentage of sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.04" spread="8.194"/>
                    <measurement group_id="O2" value="-0.54" spread="10.505"/>
                    <measurement group_id="O3" value="0.06" spread="6.888"/>
                    <measurement group_id="O4" value="-0.68" spread="6.883"/>
                    <measurement group_id="O5" value="-2.33" spread="6.600"/>
                    <measurement group_id="O6" value="-2.15" spread="5.388"/>
                    <measurement group_id="O7" value="-1.05" spread="7.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potential Habituation Effect: Comparison Between Mean Change From Baseline in Latency to Persistent Sleep (LPS) on Days 1-2 and Mean Change From Baseline in LPS on Days 14-15</title>
        <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean LPS of Days 14-15 minus change from baseline of mean LPS of Days 1-2. LPS was calculated as minutes from lights off to the first 30-second epoch of 20 consecutive epochs of non-wakefulness. A decrease in LPS indicated improvement in time needed to fall asleep.</description>
        <time_frame>Baseline and Days 1-2, and Days 14-15</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Days 1 to 15: Three E2006-matched placebo tablets were taken orally, 30 minutes before bedtime, each night for 15 consecutive nights. Days 16 to 18: Two E2006-matched placebo tablets were taken for 2 consecutive nights. Days 10 to 30: No study drug, E2006 or placebo, was taken.</description>
          </group>
        </group_list>
        <measure>
          <title>Potential Habituation Effect: Comparison Between Mean Change From Baseline in Latency to Persistent Sleep (LPS) on Days 1-2 and Mean Change From Baseline in LPS on Days 14-15</title>
          <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean LPS of Days 14-15 minus change from baseline of mean LPS of Days 1-2. LPS was calculated as minutes from lights off to the first 30-second epoch of 20 consecutive epochs of non-wakefulness. A decrease in LPS indicated improvement in time needed to fall asleep.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="24.333"/>
                    <measurement group_id="O2" value="-1.50" spread="22.120"/>
                    <measurement group_id="O3" value="-4.60" spread="22.337"/>
                    <measurement group_id="O4" value="-7.93" spread="17.415"/>
                    <measurement group_id="O5" value="-1.11" spread="24.568"/>
                    <measurement group_id="O6" value="1.38" spread="12.046"/>
                    <measurement group_id="O7" value="0.57" spread="40.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potential Habituation Effect: Comparison Between Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) on Days 1-2 and Mean Change From Baseline in WASO on Days 14-15</title>
        <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean WASO of Days 14-15 minus change from baseline of mean WASO of Days 1-2. WASO was calculated as minutes of wakefulness from the onset of persistent sleep until lights on. A decrease in WASO indicated improvement in sleep maintenance.</description>
        <time_frame>Baseline, Days 1-2, and Days 14-15</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Potential Habituation Effect: Comparison Between Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) on Days 1-2 and Mean Change From Baseline in WASO on Days 14-15</title>
          <description>Potential habituation effect evaluated the possibility of participants being habituated to changes in sleep during the 15 days of treatment with lemborexant. Data reported here was calculated as change from baseline of mean WASO of Days 14-15 minus change from baseline of mean WASO of Days 1-2. WASO was calculated as minutes of wakefulness from the onset of persistent sleep until lights on. A decrease in WASO indicated improvement in sleep maintenance.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.98" spread="34.299"/>
                    <measurement group_id="O2" value="2.16" spread="44.054"/>
                    <measurement group_id="O3" value="2.68" spread="29.726"/>
                    <measurement group_id="O4" value="9.30" spread="25.890"/>
                    <measurement group_id="O5" value="11.76" spread="26.187"/>
                    <measurement group_id="O6" value="9.28" spread="23.119"/>
                    <measurement group_id="O7" value="5.99" spread="31.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rebound Insomnia: Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 16-17</title>
        <description>Rebound insomnia was assessed by comparing the change from baseline of the mean SE on Days 16-17. Sleep efficiency was calculated as total sleep time divided by time spent in bed multiplied by 100. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep. A negative change from baseline in SE indicated that SE was worse on Days 16 and 17 than at Baseline, which was considered as evidence for rebound insomnia.</description>
        <time_frame>Baseline and Days 16-17</time_frame>
        <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, number of participants analyzed (N) represents participants who were available for analysis at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Days 1 to 15: Three E2006-matched placebo tablets were taken orally, 30 minutes before bedtime, each night for 15 consecutive nights. Days 16 to 18: Two E2006-matched placebo tablets were taken for 2 consecutive nights. Days 10 to 30: No study drug, E2006 or placebo, was taken.</description>
          </group>
        </group_list>
        <measure>
          <title>Rebound Insomnia: Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 16-17</title>
          <description>Rebound insomnia was assessed by comparing the change from baseline of the mean SE on Days 16-17. Sleep efficiency was calculated as total sleep time divided by time spent in bed multiplied by 100. An increase in SE indicated improvement in sleeping, such that, the participant spends more time in bed asleep. A negative change from baseline in SE indicated that SE was worse on Days 16 and 17 than at Baseline, which was considered as evidence for rebound insomnia.</description>
          <population>The FAS included all participants who were randomized, received at least 1 dose of study drug and had at least 1 post-dose primary efficacy measurement. Here, number of participants analyzed (N) represents participants who were available for analysis at the specified timepoint.</population>
          <units>percentage of sleep time</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.12" spread="1.661"/>
                    <measurement group_id="O2" value="15.53" spread="1.777"/>
                    <measurement group_id="O3" value="17.67" spread="1.535"/>
                    <measurement group_id="O4" value="13.78" spread="1.653"/>
                    <measurement group_id="O5" value="18.58" spread="1.253"/>
                    <measurement group_id="O6" value="17.12" spread="1.374"/>
                    <measurement group_id="O7" value="16.17" spread="1.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 16-17</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1483</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.20</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 16-17</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7720</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.96</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 16-17</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4548</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.44</ci_lower_limit>
            <ci_upper_limit>5.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 16-17</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2530</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.51</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 16-17</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1794</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>5.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Days 16-17</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6148</p_value>
            <method>ANCOVA</method>
            <method_desc>Baseline value and treatment as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.74</ci_lower_limit>
            <ci_upper_limit>4.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)</title>
        <time_frame>TEAEs: Baseline up to Day 30, SAEs: Baseline up to 30 days after last dose of study drug (up to 47 days)</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 post-dose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Days 1 to 15: Three E2006-matched placebo tablets were taken orally, 30 minutes before bedtime, each night for 15 consecutive nights. Days 16 to 18: Two E2006-matched placebo tablets were taken for 2 consecutive nights. Days 10 to 30: No study drug, E2006 or placebo, was taken.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)</title>
          <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 post-dose safety assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="40.7"/>
                    <measurement group_id="O3" value="42.1"/>
                    <measurement group_id="O4" value="59.4"/>
                    <measurement group_id="O5" value="55.4"/>
                    <measurement group_id="O6" value="60.0"/>
                    <measurement group_id="O7" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2.0"/>
                    <measurement group_id="O7" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Parameters</title>
        <time_frame>Baseline up to Day 30</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 post-dose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Days 1 to 15: Three E2006-matched placebo tablets were taken orally, 30 minutes before bedtime, each night for 15 consecutive nights. Days 16 to 18: Two E2006-matched placebo tablets were taken for 2 consecutive nights. Days 10 to 30: No study drug, E2006 or placebo, was taken.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Parameters</title>
          <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 post-dose safety assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</title>
        <time_frame>Baseline up to Day 30</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Days 1 to 15: Three E2006-matched placebo tablets were taken orally, 30 minutes before bedtime, each night for 15 consecutive nights. Days 16 to 18: Two E2006-matched placebo tablets were taken for 2 consecutive nights. Days 10 to 30: No study drug, E2006 or placebo, was taken.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</title>
          <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECGs)</title>
        <time_frame>Baseline up to Day 30</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lemborexant 1 mg</title>
            <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O2">
            <title>Lemborexant 2.5 mg</title>
            <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O3">
            <title>Lemborexant 5 mg</title>
            <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O4">
            <title>Lemborexant 10 mg</title>
            <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O5">
            <title>Lemborexant 15 mg</title>
            <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O6">
            <title>Lemborexant 25 mg</title>
            <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Days 1 to 15: Three E2006-matched placebo tablets were taken orally, 30 minutes before bedtime, each night for 15 consecutive nights. Days 16 to 18: Two E2006-matched placebo tablets were taken for 2 consecutive nights. Days 10 to 30: No study drug, E2006 or placebo, was taken.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECGs)</title>
          <population>The safety analysis set included all participants who received at least 1 dose of study drug and had at least 1 postdose safety assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="50"/>
                <count group_id="O7" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs: Baseline up to Day 30, SAEs: Baseline up to 30 days after last dose of study drug (up to 47 days)</time_frame>
      <desc>Safety analysis set included participants who received at least one dose of study drug and had at least one postdose safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lemborexant 1 mg</title>
          <description>Participants received lemborexant 1 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="E2">
          <title>Lemborexant 2.5 mg</title>
          <description>Participants received lemborexant 2.5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="E3">
          <title>Lemborexant 5 mg</title>
          <description>Participants received lemborexant 5 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="E4">
          <title>Lemborexant 10 mg</title>
          <description>Participants received lemborexant 10 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="E5">
          <title>Lemborexant 15 mg</title>
          <description>Participants received lemborexant 15 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="E6">
          <title>Lemborexant 25 mg</title>
          <description>Participants received lemborexant 25 mg tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Participants received lemborexant placebo-matching tablets, orally, once daily on Day 1 to Day 15 in the double-blind treatment phase, followed by lemborexant placebo-matching tablets, orally, once daily on Days 16 and 17 in the single-blind placebo run-out phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Excessive eye blinking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Application site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sleep paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Cataplexy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sleep phase rhythm disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid eye movements sleep abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypnagogic hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Elevated mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Hypervigilance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sleep talking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diaphragmatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Services</name_or_title>
      <organization>Eisai Inc.</organization>
      <phone>1-888-422-4743</phone>
      <email>esi_medinfo@eisai.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

